In the past week, XGN stock has gone up by 1.81%, with a monthly gain of 28.43% and a quarterly plunge of -16.56%. The volatility ratio for the week is 19.45%, and the volatility levels for the last 30 days are 15.52% for Exagen Inc The simple moving average for the past 20 days is 8.67% for XGN’s stock, with a 21.31% simple moving average for the past 200 days.
Is It Worth Investing in Exagen Inc (NASDAQ: XGN) Right Now?
Additionally, the 36-month beta value for XGN is 1.46. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for XGN is 9.17M and currently, short sellers hold a 0.19% ratio of that float. The average trading volume of XGN on April 02, 2025 was 149.43K shares.
XGN) stock’s latest price update
Exagen Inc (NASDAQ: XGN)’s stock price has gone rise by 9.47 in comparison to its previous close of 3.59, however, the company has experienced a 1.81% increase in its stock price over the last five trading days. seekingalpha.com reported 2025-03-11 that Exagen Inc. (NASDAQ:XGN ) Q4 2024 Results Conference Call March 11, 2025 8:30 AM ET Company Participants Ryan Douglas – Investor Relations John Aballi – President & Chief Executive Officer Jeff Black – Chief Financial Officer Conference Call Participants Kyle Mikson – Canaccord Genuity Ross Osborn – Cantor Fitzgerald Mark Massaro – BTIG Dan Brennan – TD Cowen Andrew Brackmann – William Blair Matthew Parisi – KeyBanc Operator Greetings, and welcome to Exagen Inc. Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Analysts’ Opinion of XGN
Cowen, on the other hand, stated in their research note that they expect to see XGN reach a price target of $26. The rating they have provided for XGN stocks is “Outperform” according to the report published on October 15th, 2021.
Canaccord Genuity gave a rating of “Buy” to XGN, setting the target price at $25 in the report published on April 15th of the previous year.
XGN Trading at 1.12% from the 50-Day Moving Average
After a stumble in the market that brought XGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.82% of loss for the given period.
Volatility was left at 15.52%, however, over the last 30 days, the volatility rate increased by 19.45%, as shares surge +30.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.50% lower at present.
During the last 5 trading sessions, XGN rose by +1.81%, which changed the moving average for the period of 200-days by +99.49% in comparison to the 20-day moving average, which settled at $3.62. In addition, Exagen Inc saw -4.15% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XGN starting from NMSIC Co-Investment Fund, L.P., who sale 350,000 shares at the price of $3.30 back on Mar 25 ’25. After this action, NMSIC Co-Investment Fund, L.P. now owns 1,758,958 shares of Exagen Inc, valued at $1,155,000 using the latest closing price.
NMSIC Co-Investment Fund, L.P., the 10% Owner of Exagen Inc, sale 200,000 shares at $3.30 during a trade that took place back on Nov 20 ’24, which means that NMSIC Co-Investment Fund, L.P. is holding 2,108,958 shares at $660,040 based on the most recent closing price.
Stock Fundamentals for XGN
Current profitability levels for the company are sitting at:
- -0.25 for the present operating margin
- 0.6 for the gross margin
The net margin for Exagen Inc stands at -0.27. The total capital return value is set at -0.44. Equity return is now at value -93.78, with -29.54 for asset returns.
Based on Exagen Inc (XGN), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at -4.17. The debt to equity ratio resting at 0.33. The interest coverage ratio of the stock is -6.1.
Currently, EBITDA for the company is -11.14 million with net debt to EBITDA at 1.69. When we switch over and look at the enterprise to sales, we see a ratio of 0.93. The receivables turnover for the company is 7.1for trailing twelve months and the total asset turnover is 1.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.70.
Conclusion
In conclusion, Exagen Inc (XGN) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
